0001521536-12-000687.txt : 20120727 0001521536-12-000687.hdr.sgml : 20120727 20120727165824 ACCESSION NUMBER: 0001521536-12-000687 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120727 DATE AS OF CHANGE: 20120727 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Honig Barry C CENTRAL INDEX KEY: 0001373203 FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 595 S FEDERAL HIGHWAY STREET 2: SUITE 600 CITY: BOCA RATON STATE: FL ZIP: 33432 FORMER COMPANY: FORMER CONFORMED NAME: Honig Barry R DATE OF NAME CHANGE: 20060818 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: DARA BioSciences, Inc. CENTRAL INDEX KEY: 0000919745 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043216862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48323 FILM NUMBER: 12991219 BUSINESS ADDRESS: STREET 1: 8601 SIX FORKS ROAD SUITE 160 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 919-861-0202 MAIL ADDRESS: STREET 1: 8601 SIX FORKS ROAD SUITE 160 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: DARA BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 FORMER COMPANY: FORMER CONFORMED NAME: POINT THERAPEUTICS INC DATE OF NAME CHANGE: 20020328 FORMER COMPANY: FORMER CONFORMED NAME: HMSR INC DATE OF NAME CHANGE: 20010618 SC 13G/A 1 q1100641_13ga-dara.htm Unassociated Document

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

DARA BioSciences, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

23703P106
(CUSIP Number)

December 31, 2011
 (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨      Rule 13d-1(b)

x      Rule 13d-1(c)

¨      Rule 13d-1(d)
 
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 
 

CUSIP No. 23703P106
13G
Page 2 of 4 Pages

1
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Barry Honig
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
(a)¨ 
 
(b)¨ 
   
3
SEC USE ONLY
 
 
4 
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
 
 
                               
NUMBER OF
5
 SOLE VOTING POWER
 
 728,053 (1)(2)
SHARES
BENEFICIALLY
OWNED BY
6
 SHARED VOTING POWER
    
 
EACH
REPORTING
PERSON
7
 SOLE DISPOSITIVE POWER
 
 728,053 (1)(2)
WITH
 
8
 SHARED DISPOSITIVE POWER
 
    
9
 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 728,053
 
10
 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
 
¨ 
   
11
 
 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 7.2% (3)
  
12
 
 TYPE OF REPORTING PERSON*
 In - Individual
 

 
(1)
Represents shares of common stock held individually by the reporting person.
 
(2)
Does not include shares issuable upon the exercise or conversion of: 105,400 warrants owned directly by the reporting person; 293,167 warrants owned by GRQ Consultants, Inc. 401K; 120,000 warrants owned by GRQ Consultants, Inc. Defined Benefit Plan; and 619,308 warrants and 350 shares of Series B Preferred Stock owned by Marlin Capital Investments, Inc.  All warrants and preferred stock are subject to a 4.99% beneficial ownership limitation.  The reporting person is the trustee of GRQ 401K and GRQ Defined Benefit Plan, and, in such capacity, has voting and dispositive power over the securities held by GRQ 401K and GRQ Defined Benefit Plan.  The reporting person shares voting and dispositive power over the securities held by Marlin Capital.
 
(3)
Based on 10,102,973 shares outstanding.

 
 
 

CUSIP No. 23703P106
13G
Page 3 of 4 Pages

Item 1.

(a)
Name of Issuer: DARA BioSciences, Inc.
(b)
Address of Issuer’s Principal Executive Offices: 8601 Six Forks Road, Suite 160, Raleigh, North Carolina 27615

Item 2.

(a)
Name of Person Filing: Barry Honig
(b)
Address of Principal Business Office: 4400 Biscayne Boulevard, Suite 850, Miami, FL  33137
(c)
Citizenship: United States of America
(d)
Title of Class of Securities: Common Stock
(e)
CUSIP Number: 23703P106

Item 3.
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable.

Item 4.
Ownership.

See Item 5 through 9 and 11 of cover page.

Item 5.
Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6.
Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable.

Item 8.
Identification and Classification of Members of the Group.

Not Applicable.

Item 9.
Notice of Dissolution of Group.

Not Applicable.

Item 10.
Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction have that purpose or effect.

 
 
 

CUSIP No. 23703P106
13G
Page 4 of 4 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: July 26, 2012

/s/ Barry Honig
Barry Honig, Individual